synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
== Plasmid preparation == Chloramphenicol is often used when growing E. coli cultures intended for plasmid preparation. Chloramphenicol halts protein synthesis, but allows plasmids with a relaxed origin of replication to keep replicating, thus improving yield.
== Structure == PGLYRP2 has one canonical carboxy-terminal catalytic peptidoglycan-binding type 2 amidase domain (also known as a PGRP domain) with predicted peptidoglycan-binding and catalytic cleft with walls formed by α-helices and the floor by a β-sheet. PGLYRP2 also has a long N-terminal segment that comprises two thirds of the PGLYRP2 sequence, has two hydrophobic regions, is unique and not found in other mammalian PGLYRP1, PGLYRP3, and PGLYRP4 and in invertebrate PGRPs, and contains intrinsically disordered region with hepatitis B virus (HBV) DNA-binding domain. The C-terminal segment is also longer than in other mammalian PGLYRPs. PGLYRP2 has two pairs of cysteines in the PGRP domain that are conserved in all human PGRPs and are predicted to form two disulfide bonds. Human PGLYRP2 is glycosylated and secreted, and forms non-disulfide-linked homodimers. PGLYRP2, similar to all other amidase-active PGRPs (invertebrate and vertebrate), has a conserved Zn2+-binding site in the peptidoglycan-binding cleft, which is also present in bacteriophage type 2 amidases and consists of two histidines, one tyrosine, and one cysteine (His411, Tyr447, His522, Cys530 in human PGLYRP2).
dropping point The temperature at which a grease changes from a semi-solid to a liquid state under standardized conditions, i.e. the upper limit at which the grease retains its structure, though not necessarily the maximum temperature at which it can be used.
== External links == UK New Year Honours List 2024 International list Guernsey Jersey Isle of Man Royal Navy Army Royal Air Force Home Office Police King's Ambulance Medal Overseas Territories Police Medal
Sources: en.wikipedia.org
The serum total clearance of CPA is approximately 2.32 ± 0.38 mL/min/kg. Levels of CPA and 15β-OH-CPA with oral administration decrease biphasically over a period of 24 to 120 hours. The elimination of CPA appears to be biphasic. In one study, a peak at 3.4 hours post-dose with an initial half-life of 3.4 hours and later half-life of 1.6 days was observed following a single 50 mg oral dose of CPA. The high lipophilicity and fat storage of CPA may be the reason for its longer subsequent half-life.
=== Rejuva === Rejuva is an adeno-associated virus (AAV)-based gene therapy platform to enable the pancreas to produce GLP-1 on an ongoing basis as a treatment for obesity and type 2 diabetes. The therapy targets dysfunctional beta islet cells in the pancreas. Delivery is done with a needle catheter to deliver viral vectors into the pancreas. In January 2025, Rejuva completed Clinical Trial Application-enabling preclinical in vivo studies, beginning its first-in-human studies in the first half of 2025.
== Classification of MMC == MMC can be classified into physical MMC and chemical MMC. In the former method, the stationary phase is constructed of two or more types of packing materials. In the chemical method, just one type of packing material containing two or more functionalities is used.
A radium industry developed, using radium in creams, beverages, chocolates, toothpastes, and soaps. It took a relatively long time for radium and its decay product radon to be recognized as the cause of the observed effects. Radithor, a radioactive agent consisting of triple-distilled water in which the radium isotopes 226Ra and 228Ra were dissolved so that it had an activity of at least one microcurie, was marketed in the United States. It was not until 1932, when the prominent American athlete Eben Byers, who by his own account had taken about 1,400 vials of Radithor as medicine on the recommendation of his physician, fell seriously ill with cancer, lost many of his teeth, and died shortly thereafter in great agony, that strong doubts were raised about the healing powers of Radithor and radium water.
=== Single gene disorders === Autosomal dominant and recessive single gene disorders which have been diagnosed prenatally by analysing paternally inherited DNA include cystic fibrosis, beta thalassemia, sickle cell anemia, spinal muscular atrophy, and myotonic dystrophy. Prenatal diagnosis of single gene disorders which are due to an autosomal recessive mutation, a maternally inherited autosomal dominant mutation or large sequence mutations that include duplication, expansion or insertion of DNA sequences is more difficult. In cffDNA, fragments of 200 – 300 bp length involved in single gene disorders are more difficult to detect. For example, the autosomal dominant condition, achondroplasia is caused by the FGFR3 gene point mutation. In two pregnancies with a fetus with achondroplasia was found a paternally inherited G1138A mutation from cffDNA from a maternal plasma sample in one and a G1138A de novo mutation from the other. In studies of the genetics of Huntington's chorea using qRT-PCR of cffDNA from maternal plasma samples, CAG repeats have been detected at normal levels (17, 20 and 24). cffDNA may also be used to diagnose single gene disorders. Developments in laboratory processes using cffDNA may allow prenatal diagnosis of aneuploidies such as trisomy 21 (Down syndrome) in the fetus.
Sources: en.wikipedia.org
=== Dosage forms === Prednisolone is supplied as oral liquid, oral suspension, oral syrup, oral tablet, and oral disintegrating tablet. It may be a generic medication or supplied as brands Flo-Pred (prednisolone acetate oral suspension), Millipred (oral tablets), Orapred (prednisolone sodium phosphate oral dissolving tablets), Pediapred (prednisolone sodium phosphate oral solution), Veripred 20, Prelone, Hydeltra-T.B.A., Hydeltrasol, Key-Pred, Cotolone, Predicort, Medicort, Predcor, Bubbli-Pred, Omnipred, P-Pred (prednisolone acetate ophthalmic suspension), Pred Mild, Pred Forte, and others.
=== March === 8 March The report of a 20-year survey by The Botanical Society of Britain and Ireland revealed that 56% of Ireland's native plant species are in decline due to habitat loss, altered grazing pressure, and degradation (re-seeding, over-fertilising, nitrogen deposition, herbicides, soil drainage, mineral enrichment), rather than rising temperatures whose botanical effects – so far – are minor. By contrast, 80% of non-native plants introduced into Ireland since 1500 have increased. The Taoiseach Leo Varadkar marked International Women's Day by announcing the Government's intention to hold a referendum to enshrine gender equality in the Constitution by amending Articles 40 and 41. 13 March – President of the United States Joe Biden announced that he will visit Ireland, north and south, in April for the 25th anniversary of the Good Friday Agreement (signed on 10 April 1998). It was reported two weeks later that Biden will arrive in Belfast on 11 April, then he will be based in Dublin from 12 to 15 April from where he will make trips to other parts of the country. Former US president Bill Clinton and his wife Hillary will visit Belfast the following week. 15 March – 46-year-old Stephen Silver was found guilty of the capital murder of Detective Garda Colm Horkan who was shot dead in Castlerea, County Roscommon in June 2020. 16 March – Ryan Tubridy announced that he would be stepping down as the presenter of The Late Late Show after 14 years, with his last show in May.
== Arts and entertainment == Eighth octave C, a musical note, the highest on a piano Castle Infinity, the first graphical massively multiplayer online game C8 (French TV channel), a defunct French TV channel C8 (Eastern Europe), TV channel
Radioiodine Therapy (RIT) is a nuclear medicine procedure used to treat thyroid hyperfunction, Graves' disease, thyroid enlargement, and certain forms of thyroid cancer. The radioactive iodine isotope used is 131Iodine, a predominant beta emitter with a half-life of eight days, which is only stored in thyroid cells in the human body. In 1942, Saul Hertz (1905-1950) of the Massachusetts General Hospital and the physicist Arthur Roberts published their report on the first radioiodine therapy (1941) for Graves' disease, at that time still predominantly using the 130iodine isotope with a half-life of 12.4 hours. At the same time, Joseph Gilbert Hamilton (1907-1957) and John Hundale Lawrence (1904-1991) performed the first therapy with 131iodine, the isotope still used today. Radioiodine therapy is subject to special legal regulations in many countries, and in Germany may only be performed on an inpatient basis. There are approximately 120 treatment centers in Germany (as of 2014), performing approximately 50,000 treatments per year. In Germany, the minimum length of stay is 48 hours. Discharge depends on the residual activity remaining in the body. In 1999, the limit for residual activity was raised. The dose rate may not exceed 3.5 μSv per hour at a distance of 2 meters from the patient, which means that a radiation exposure of 1 mSv may not be exceeded within one year at a distance of 2 meters. This corresponds to a residual activity of about 250 MBq. Similar regulations exist in Austria.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.